Friday, June 02, 2023 6:53:43 AM
I'm glad you appreciate the information I share on this board. It's important to be informed when making investment decisions, especially when it comes to penny stocks. I've been researching and exposing scams in the market for a while now, including the infamous Spencer Pharmaceuticals case, where I helped uncovered false claims of a buyout.
Regarding VPLM, I understand your concerns and it's great that you've independently verified certain red flags. It's crucial to consider all available facts and well-reasoned arguments when assessing an investment. Now, let's address the offer from Gil Amileo and how it fits into the scam thesis.
Firstly, it's important to recognize that many fraudulent schemes utilize false announcements of mergers, acquisitions, and buyouts to manipulate stock prices positively. These claims are designed to create an illusion of legitimacy and attract unsuspecting investors. This tactic has been employed in numerous penny stock scams in the past.
In the case of VPLM, the press release about the offer from Dr. Amelio may have been part of such a strategy. It's possible that the offer itself was not genuine and was merely a ploy to boost investor confidence and increase the stock price. If that were the case, Dr. Amelio might not have publicly disputed the press release as it would have been aligned with the manipulative intentions.
Moreover, even if the offer were real, it doesn't necessarily disprove the scam thesis. Scammers often create elaborate facades to deceive investors, and a seemingly substantial offer can be part of that deception. By rejecting the offer and opting for smaller periodic amounts, scammers can maintain the illusion of long-term value and sustainability, which keeps investors hooked and prolongs their scheme.
Recent VPLM News
- ILUS International Inc (ILUS) Sees 557% Q1 Revenue Increase, Begins National Exchange Uplist Procedure for Subsidiaries and Company • InvestorsHub NewsWire • 06/05/2023 12:15:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM